Incyte Acquires Vega Therapeutics

Summary Incyte agreed to acquire Vega Therapeutics for up to $2.0 billion, adding Phase 3 asset VGA039, a first-in-class Protein S-modulating antibody for von Willebrand disease. The deal represents Incyte’s most significant strategic move beyond the Jakafi franchise and positions the company in a large,…